Free Trial
NASDAQ:FNCH

Finch Therapeutics Group (FNCH) Stock Price, News & Analysis

Finch Therapeutics Group logo
$13.00 +0.75 (+6.12%)
As of 08/28/2025 03:58 PM Eastern

About Finch Therapeutics Group Stock (NASDAQ:FNCH)

Key Stats

Today's Range
$12.03
$13.00
50-Day Range
$12.00
$13.48
52-Week Range
$10.15
$15.85
Volume
287 shs
Average Volume
2,182 shs
Market Capitalization
$20.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Finch Therapeutics Group Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
6th Percentile Overall Score

FNCH MarketRank™: 

Finch Therapeutics Group scored higher than 6% of companies evaluated by MarketBeat, and ranked 932nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Finch Therapeutics Group.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Finch Therapeutics Group is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Finch Therapeutics Group is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Finch Therapeutics Group has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.01% of the float of Finch Therapeutics Group has been sold short.
  • Short Interest Ratio / Days to Cover

    Finch Therapeutics Group has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • Dividend Yield

    Finch Therapeutics Group does not currently pay a dividend.

  • Dividend Growth

    Finch Therapeutics Group does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.01% of the float of Finch Therapeutics Group has been sold short.
  • Short Interest Ratio / Days to Cover

    Finch Therapeutics Group has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • News Coverage This Week

    MarketBeat has tracked 1 news article for Finch Therapeutics Group this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Finch Therapeutics Group insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    44.90% of the stock of Finch Therapeutics Group is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 21.77% of the stock of Finch Therapeutics Group is held by institutions.

  • Read more about Finch Therapeutics Group's insider trading history.
Receive FNCH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Finch Therapeutics Group and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

FNCH Stock News Headlines

He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.tc pixel
FNCH Finch Therapeutics Group, Inc. - Seeking Alpha
Arquitos Capital's Largest Holdings For Q1 2025
Arquitos Capital Management Q4 2024 Commentary
Finch Therapeutics announces Nasdaq delisting, SEC deregistration
See More Headlines

FNCH Stock Analysis - Frequently Asked Questions

Finch Therapeutics Group's stock was trading at $11.30 on January 1st, 2025. Since then, FNCH stock has increased by 15.0% and is now trading at $13.00.

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) announced its earnings results on Wednesday, November, 10th. The company reported ($6.30) earnings per share for the quarter, topping the consensus estimate of ($12.60) by $6.30. The firm earned $11.34 million during the quarter.

Finch Therapeutics Group shares reverse split on Monday, June 12th 2023.The 1-30 reverse split was announced on Monday, June 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Finch Therapeutics Group (FNCH) raised $101 million in an IPO on Friday, March 19th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO.

Shares of FNCH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Finch Therapeutics Group investors own include CNS Pharmaceuticals (CNSP), Faraday Future Intelligent Electric (FFIE), Allarity Therapeutics (ALLR), Aridis Pharmaceuticals (ARDS), Meta Platforms (META), NVIDIA (NVDA) and Altamira Therapeutics (CYTO).

Company Calendar

Last Earnings
11/10/2021
Today
8/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:FNCH
CIK
1733257
Fax
N/A
Employees
190
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($8.82)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$74.75 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-69.14%
Return on Assets
-26.92%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.87
Quick Ratio
3.87

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$14.25 per share
Price / Book
0.91

Miscellaneous

Outstanding Shares
1,606,000
Free Float
885,000
Market Cap
$20.88 million
Optionable
No Data
Beta
1.19
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:FNCH) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners